Illiquid Gold: Creative Dealmaking in Biotech

Evaluate and Treehill Partners discuss the state of play and look for smart ways to get investment and deals moving as we head into 2023.

Cem Baydar and Paul Verdin from Evaluate are joined by Ali Pashazadeh, Max Baumann, and Mark Mayhew from Treehill Partners to discuss the latest dealmaking data, the pipeline pitfalls to avoid, and more.

View the webinar to get insights on:

  • The latest IPO, M&A, and share price data
  • How a changing ecosystem requires innovative intervention
  • Optimal deal structures
  • The importance of good preparation and due diligence

Industry trends

Share This Article

 
Illiquid Gold Presentation

To revisit the data, please download the webinar slides

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.